Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD

Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and tha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigative ophthalmology & visual science 2011-07, Vol.52 (7), p.4694
Hauptverfasser:	Kloeckener-Gruissem, Barbara, Barthelmes, Daniel, Labs, Stephan, Schindler, Christian, Kurz-Levin, Malaika, Michels, Stephan, Fleischhauer, Johannes, Berger, Wolfgang, Sutter, Florian, Menghini, Moreno
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Complement Factor B - genetics Complement Factor H - genetics DNA - analysis DNA - genetics Dose-Response Relationship, Drug Female Fluorescein Angiography Follow-Up Studies Fundus Oculi Genetic Predisposition to Disease Genotype High-Temperature Requirement A Serine Peptidase 1 Humans Intravitreal Injections Macular Degeneration - diagnosis Macular Degeneration - drug therapy Macular Degeneration - genetics Male Polymerase Chain Reaction Polymorphism, Genetic Proteins - genetics Ranibizumab Retinal Neovascularization - diagnosis Retinal Neovascularization - drug therapy Retinal Neovascularization - genetics Serine Endopeptidases - genetics Time Factors Tomography, Optical Coherence Vascular Endothelial Growth Factor A - genetics Visual Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!